Mabpharm Limited will convene its 2026 annual general meeting (AGM) on 26 June 2026 at 2:00 p.m. in Shanghai (No. 301 Libing Road, Zhangjiang Hi-Tech Park, Pudong New District). The meeting will seek shareholder approval on routine annual matters and several capital management resolutions.

The ordinary resolutions include:

• Financial Statements: Receiving and considering the audited consolidated financial statements and the directors’ and auditors’ reports for the financial year ended 31 December 2025.

• Board Composition: Re-election of four directors—executive directors Li Yunfeng, Tao Jing and Hou Sheng, along with independent non-executive director Louis Ho Ming Leung—plus authorisation for the board to determine directors’ remuneration.

• Auditor: Re-appointment of Ernst & Young as external auditor and authorisation for the board to set its remuneration.

• Share Repurchase Mandate: Granting the board a general mandate to repurchase up to 10% of the company’s issued share capital as at the date of the AGM.

• Share Issuance Mandate: Granting the board a general mandate to issue, allot and deal with new shares representing up to 20% of issued capital, with authority to extend this mandate by the number of shares repurchased under the preceding authorisation.

A special resolution will also be tabled to adopt a new memorandum and articles of association, updating the company’s constitutional documents.

Shareholders wishing to vote by proxy must submit completed forms to Computershare Hong Kong Investor Services Limited by 2:00 p.m. on 24 June 2026, at least 48 hours before the meeting. Completion and return of a proxy form will not preclude shareholders from attending and voting in person.